BMO downgrades Biogen, asserts company is spending too much on controversial Alzheimer's drug
[ad_1]
Biogen's new Alzheimer's drug aduhelm saw limited pickup in its first few months on the market.
[ad_2]
[ad_1]
Biogen's new Alzheimer's drug aduhelm saw limited pickup in its first few months on the market.
[ad_2]